HIBERIX is a monovalent PRP-tetanus toxoid conjugate vaccine that has been available outside the United States since 19961
- HIBERIX is registered in nearly 100 countries
- Approximately 54 million doses of HIBERIX have been distributed outside the US
Learn more about HIBERIX – a Hib vaccine for the millions of children who need a
booster dose
Indication
HIBERIX is indicated for active immunization as a booster dose for the prevention of invasive disease caused by Haemophilus influenzae type b (Hib). HIBERIX is approved for use in children 15 months through 4 years of age (prior to fifth birthday).
Important Safety Information
- In clinical studies, adverse events in children receiving HIBERIX included pain and redness at the injection site, fever, fussiness, loss of appetite, and restlessness
- A severe allergic reaction (eg, anaphylaxis) after a previous dose of any Hib or tetanus toxoid-containing vaccine or any component of HIBERIX is a contraindication
- If Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior vaccine containing tetanus toxoid, the decision to give HIBERIX should be based on potential benefits and risks
- Vaccination with HIBERIX may not protect 100% of susceptible individuals
References: 1. Data on file, GlaxoSmithKline.